Loading stock data…
$88.17+1.95 (+2.26%)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
ABIVAX Société Anonyme in the Healthcare sector is trading at $88.17 with a market capitalization of $7.2B. Wall Street consensus targets $163.58 (12 analysts), implying a +85.5% move over the next 12 months. The stock is currently 41% below its 52-week high of $148.83, remaining 24.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$56.23M↑ | -$71.65M↑ | -$80.71M↓ | -$46.50M↑ | -$47.20M |
| Net Income | -$48.47M↑ | -$81.96M↑ | -$153.36M↓ | -$48.41M↑ | -$52.37M |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate inclu...